Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639284 | 0.87 | MEN1 (0.36) | KMT2AMEN1TDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27804377 | 0.82 | CYP11B1 (0.40) | KMT2ACYP3A4CYP2C9MEN1LMNA | |
| SCHEMBL2203211 | 0.81 | CDC25B (0.49) | KMT2ACYP3A4CYP2C9MEN1LMNA | |
| SCHEMBL1639289 | 0.80 | CYP46A1 (0.36) | KMT2ACYP3A4CYP2C9MEN1LMNA | |
| SCHEMBL8365795 | 0.79 | ALDH1A1 (0.35) | CYP3A4CYP2C9LMNATDP1CYP1A2 | |
| SCHEMBL11891101 | 0.78 | KMT2A (0.41) | KMT2AMEN1LMNATDP1AKR1C3 | |
| SCHEMBL3070579 | 0.78 | KAT6A (0.37) | KMT2ACYP3A4CYP2C9MEN1LMNA | |
| SCHEMBL3029621 | 0.77 | ALDH1A1 (0.44) | KMT2AMEN1LMNAKDM4EHTT | |
| SCHEMBL11891094 | 0.77 | ALDH1A1 (0.41) | KMT2ACYP3A4CYP2C9LMNATDP1 | |
| SCHEMBL7683395 | 0.76 | ALDH1A1 (0.46) | KMT2ACYP3A4CYP2C9MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2250153-B1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2079706-B1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS JSC (LV) | 2011-07-20 | — | — | EP | disclosed |
| EP-2240453-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-02-25 | — | — | US | disclosed |
| WO-2009091735-A1 | SUBSTITUED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN.INC (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-2079706-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2008055852-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | disclosed |
| EP-1918282-A1 | Method for preparing medetomidine and its salts | "Joint Stock Company Grindeks" (LV) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | ADRB2, ADRB3, OPRM1 | KMT2A 151/4885CYP3A4 12/4885CYP2C9 54/4885 |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRB3 | KMT2A 1256/4885CYP3A4 303/4885CYP2C9 326/4885 |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB3, ADRB2 | KMT2A 2593/4885CYP3A4 356/4885CYP2C9 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.